Contact Info

Sameeh Salama

Chief Scientific Officer - Fedora Pharmaceuticals

Dr. Salama has more than 25 years drug discovery experience across several disciplines including the discovery and development of new antibacterial and antifungal agents. In addition to being the Chief Scientific Officer (CSO) of Fedora Pharmaceuticals Inc. (, he is also the CSO of Brass Dome Ventures Ltd.(; an active member of the Multi-sectoral Federal Provincial and Territorial Task Group on Antimicrobial Resistance for the Government of Canada; Chairman of the Steering Committee of the Canadian Antimicrobial (AMR) Resistance Innovation Coalition (CAIC); Director on the Board of Directors of Alberta (, a biotechnology advocacy group representing the biotechnology sector of the Province of Alberta, Canada; Chairman of the Board of Al Rashid Education Foundation (, a not-for-profit organization promoting post-secondary education of marginalized communities; and involved in a number of not-for-profit organizations. He also held several senior positions in both the drug discovery and contract research sectors, including several vice-president roles.

In his scientific capacity, Dr. Salama played a senior role in the discovery and development ofantibiotics including beta-lactmas, beta-lactamase inhibitors, fluoroquinolones, azoles, polyenes, as well as several natural products.

Additionally, Dr. Salama is business development professional with nearly 20-year experience in strategic planning, evaluation of new business and scientific opportunities, partnership and management, contract negotiations, as well as in-licensing and out-licensing of assets. He was actively involved in dozens of licensing and partnership agreements, including the licensing of Fedora’s Beta-lactamase inhibitors to F. Hoffman La Roche in a US$750 million license deal.

Dr. Salama received his Ph.D. in Microbiology from the University of Salford, UK, and published over 50 original research articles and presentations at international congresses. He is also an inventor on several original patents in the anti-infective and anti-inflammatory disease areas.